Clearmind Says US Patent Application Published Targeting Binge Behavior Disorders
MT Newswires Live
Oct 20, 2025
Clearmind Medicine (CMND) said Monday that a US patent application has been published by the US Patent and Trademark Office for its innovative combination therapy of 5-methoxy-2-aminoindane and N-Acylethanolamines, such as Palmitoylethanolamide, targeting binge behavior disorders.
The clinical-stage biotech company said this patent application stems from its ongoing collaboration with SciSparc (SPRC), and that this therapy targets multiple binge behaviors, including excessive alcohol consumption binge eating, smoking, compulsive shopping, and problematic sexual conduct.
Clearmind Medicine shares were up less than 1% in recent Monday premarket activity, while SciSparc's were up 23%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.